Cellect Biotechnology develops solutions for immune system regeneration. Its platform technology is based on the idea that the functional properties of stem cells, rather than their appearance, should be used for their identification, selection, and utilization.
The companys first product is designed to harness the critical function of sensitivity to specific apoptosis-inducing agents. These molecules induce apoptosis in mature cells while sparing stem cells, and this differential sensitivity is used to dramatically improve the outcome of bone marrow transplants.
By achieving selectivity, specificity, and decreased toxicity, Cellect Biotechnology envisions its products becoming an integral and essential part of bone marrow transplants and being integrated into many aspects of regenerative medicine.
In January 2018, Cellect Biotechnology signed an agreement with Hadassah Medical Center to conduct a clinical trial of the companys ApoGraft.
In April 2018, the company announced it had completed POC testing for the first scalable production of ApoTainer, which is designed to replace the highly complex and expensive procedures currently used by laboratories (e.g. bone marrow transplants), providing a significantly more effective process at a fraction of the time and cost.